Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

Head and neck cancer patients went disease-free for five years, compared to half that time for people undergoing standard ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Immunotherapy drug delays cancer recurring or worsening in global trial - A new study found the drug kept head and neck ...

Hundreds of thousands of people with advanced head and neck cancer could live longer without their cancer returning thanks to ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do ...

Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

An immunotherapy drug could help some cancer patients live years longer without the disease worsening or recurring, according to a new trial. The study revealed that pembrolizumab, sold under the ...